Shanghai Pharmaceuticals Holding Co., Ltd (SHPMF)
OTCMKTS
· Delayed Price · Currency is USD
1.562
-0.008 (-0.51%)
Mar 31, 2025, 4:00 PM EST
SHPMF Revenue
In the year 2024, Shanghai Pharmaceuticals Holding had annual revenue of 274.19B CNY with 5.80% growth. Shanghai Pharmaceuticals Holding had revenue of 64.56B in the quarter ending December 31, 2024, with 4.73% growth.
Revenue
274.19B CNY
Revenue Growth
+5.80%
P/S Ratio
n/a
Revenue / Employee
5.69M CNY
Employees
48,164
Market Cap
8.45B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 274.19B | 15.03B | 5.80% |
Dec 31, 2023 | 259.15B | 27.17B | 11.71% |
Dec 31, 2022 | 231.98B | 16.16B | 7.49% |
Dec 31, 2021 | 215.82B | 23.92B | 12.46% |
Dec 31, 2020 | 191.91B | 5.34B | 2.86% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
SS Innovations International | 16.04M |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 200.90M |
Northwest Biotherapeutics | 1.60M |
Silence Therapeutics | 43.26M |
American Oncology Network | 1.76B |
Shanghai Pharmaceuticals Holding News
- 3 months ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
- 3 months ago - HUTCHMED to divest 45% stake in JV with Shanghai Pharma - Seeking Alpha